In the theater of American rhetoric, names are often chosen for their ability to soothe or signal. The "Department of War" became the "Department of Defense"; today, "vaccines" are being recast as "individualized neoantigen therapies." For Moderna, the biotech pioneer of the pandemic era, this semantic shift is a tactical necessity. As political winds shift and skepticism toward mRNA technology hardens within the federal government, the company is finding that its scientific nomenclature must be as adaptive as its molecular platforms.
The pressure is tangible. Under the leadership of Robert F. Kennedy Jr. at the Department of Health and Human Services, the federal government has begun dismantling support for mRNA research, including the withdrawal of a $776 million grant for avian flu preparedness. With contracts canceled and regulatory hostility mounting, Moderna has signaled that it may have to abandon late-stage vaccine programs for infectious diseases entirely. The company is, in effect, being squeezed out of the public health space it helped define.
From Vaccine to Therapy: The Strategic Logic of Relabeling
This retreat has shifted the spotlight to Moderna's oncology partnership with Merck. The technology remains fundamentally the same: mRNA is used to sequence a patient's tumor, identifying unique molecules — neoantigens — that can be used to train the immune system to attack cancer. While historically categorized as "cancer vaccines," the term has become a political third rail. To navigate this, the companies have pivoted to a more clinical, less controversial label: individualized neoantigen therapy.
The maneuver is not without scientific justification. Traditional vaccines are prophylactic — they prevent disease before it occurs. Cancer "vaccines" of the kind Moderna and Merck are developing are therapeutic: they are administered after diagnosis, tailored to the molecular signature of an existing tumor. The distinction between prevention and treatment has always made the "vaccine" label somewhat imprecise in oncology. What has changed is not the science but the cost of imprecision. In a regulatory environment where the word "vaccine" triggers political resistance, taxonomic accuracy and commercial survival have converged.
The pattern has precedent. Pharmaceutical companies have long understood that nomenclature shapes both public perception and regulatory pathways. The history of drug development is littered with rebranding exercises designed to reposition products for friendlier reception — whether by insurers, regulators, or patients. What makes the Moderna case distinctive is the directness of the political catalyst. The relabeling is not driven by marketing focus groups or reimbursement strategy alone; it is a response to an active contraction of federal support for an entire class of technology.
The Broader Stakes for mRNA as a Platform
The implications extend well beyond a single product line. mRNA technology, which gained global visibility through COVID-19 vaccines, was always envisioned as a broader platform — applicable to infectious diseases, rare genetic conditions, and oncology alike. Moderna's pipeline reflected that ambition. The withdrawal of federal funding and the cancellation of government contracts now threaten to narrow the platform's commercial viability to areas where the "vaccine" label can be avoided.
This creates a peculiar dynamic. The same technology that delivered one of the fastest vaccine developments in history is now being strategically distanced from the category that made it famous. For the mRNA field as a whole, the risk is that political headwinds do not merely slow one company's progress but reshape which applications receive investment and which are quietly shelved. Oncology, where treatments command high prices and patient advocacy is strong, offers a more defensible commercial position than infectious disease prevention, which depends heavily on public funding and government procurement.
The tension, then, is structural. On one side sits a technology platform with demonstrated versatility and a growing body of clinical evidence in cancer treatment. On the other sits a political environment that has turned a scientific term into a liability. Whether the relabeling proves sufficient to insulate Moderna's oncology work from broader anti-mRNA sentiment — or whether the skepticism follows the molecule regardless of what it is called — remains the central question. The answer will likely say as much about the relationship between science and politics in the United States as it does about the future of any single therapy.
With reporting from MIT Tech Review Brasil.
Source · MIT Tech Review Brasil
